VCNX Vaccinex Inc.: Enterprise Value-to-Revenue Multiple

Public company logo of vaccinex.com (VCNX)

Vaccinex, Inc. (VCNX) attracts leading clinicians through promising developments in oncology. Professional management is effectively advancing therapeutic platforms, and on GURU.Markets, this EV/Sales trajectory clearly confirms the market valuation, where the current parameter equals . The company's operations are strictly limited by FDA medical regulations, which guarantees compliance with basic environmental standards during the disposal of biomaterials.

Company Value to Revenue: Vaccinex Inc. (VCNX) for 07/04/2022 - 11/20/2026

vaccinex.com - analytical breakdowns and key metrics (VCNX)

- share price and consensus valuation forecast:
Initial company analysis:Vaccinex, Inc. VCNX
Product sample of Vaccinex, Inc.

The market evaluates Vaccinex, Inc. (VCNX) through a lens of high risk due to liquidity shortages and frequent secondary offerings to support oncology research. By analyzing the firm's valuation via the EV/Sales multiple, an investor views the ratio of enterprise value (market capitalization plus debt minus cash) to revenue, which allows them to filter out speculative noise and determine the asset's actual fundamental stability against a backdrop of volatile sales.

Competitor analysis for Vaccinex, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|INTS - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Sensei Biotherapeutics Inc SNSE|TOVX: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gritstone Bio (GRTS)|KA (Kineta Corp) - EV/Sales Multiple|Company Value to Revenue Ratio NEXI (NexImmune Corp)|EV/Sales Multiple TSBX|Enterprise Value-to-Revenue Coefficient HARP